A Digital Platform to Optimize Guideline Directed Heart Failure Therapy: Rationale and Design of the AIM-POWER Trial

By sjmartinez • March 24, 2025

DeVore AD, Xie J, Etters L, Rael E, Wibowo S, Hao C, Majmudar M, Hernandez AF, Fonarow GC, Desai AS. A Digital Platform to Optimize Guideline Directed Heart Failure Therapy: Rationale and Design of the AIM-POWER Trial. J Card Fail. 2025 Mar 21:S1071-9164(25)00143-5. doi: 10.1016/j.cardfail.2025.02.018. Epub ahead of print. PMID: 40122512.

Tags: Cardiology/Epi, clinical trials, digital therapeutics, heart failure, Publications

Surviving the Odds: Primary Cardiac Lymphoma With Locoregional Lymph Node Involvement Complicated by Pericardial Effusion and Arrhythmia

Bachour K, Shah S, Reichl A, Chia J, Shabsovich DS, Castillo A, Cho G. Surviving the Odds: Primary Cardiac Lymphoma With Locoregional Lymph Node Involvement[...]

Aortic valve calcium as a novel risk marker for kidney function deterioration: The MESA study

Abdollahi A, Sani MM, Shabani M, Matuck BS, Blaha MJ, Wu CO, Ambale-Venkatesh B, Budoff MJ, Strom JB, Rotter JI, Post WS, Blumenthal RS, Bluemke[...]

Mutual Regulation of Cardiovascular and Hematopoietic Development

Liu N, Nakano H, Nakano A. Mutual Regulation of Cardiovascular and Hematopoietic Development. Curr Cardiol Rep. 2025 Apr 22;27(1):86. doi: 10.1007/s11886-025-02236-5. PMID: 40261519.